SLC5A2 and heart failure: More recently, it has been found that canagliflozin improves symptoms in patients with heart failure with preserved ejection fraction (HFpEF) [38], which seems to be a unique feature of this SGLT2 inhibitor, as all other medications have been shown to improve prognosis in those patients.